Pooled secondary analysis of 3 phase 3 placebo-controlled COPD trials: mepolizumab reduced, or trended to reduce, moderate/severe exacerbations with persistently (12%-27%) or variably (22%-36%) raised blood eosinophils; no benefit with persistently low counts (<150 cells/µL).
Secondary analysis
Criner et al. Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials